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Abstract
Background
Feedback of potentially serious incidental findings (PSIFs) to imaging research participants
generates clinical assessment in most cases. Understanding the factors associated with
increased risks of PSIFs and of serious final diagnoses may influence individuals’ decisions
to participate in imaging research and will inform the design of PSIFs protocols for future
research studies. We aimed to determine whether, and to what extent, socio-demographic,
lifestyle, other health-related factors and PSIFs protocol are associated with detection of
both a PSIF and a final diagnosis of serious disease.
Methods and findings
Our cohort consisted of all UK Biobank participants who underwent imaging up to December
2015 (n = 7334, median age 63, 51.9% women). Brain, cardiac and body magnetic reso-
nance, and dual-energy x-ray absorptiometry images from the first 1000 participants were
reviewed systematically by radiologists for PSIFs. Thereafter, radiographers flagged con-
cerning images for radiologists’ review. We classified final diagnoses as serious or not
using data from participant surveys and clinical correspondence from GPs up to six months
following imaging (either participant or GP correspondence, or both, were available for 93%
of participants with PSIFs). We used binomial logistic regression models to investigate
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associations between age, sex, ethnicity, socio-economic deprivation, private healthcare
use, alcohol intake, diet, physical activity, smoking, body mass index and morbidity, with
both PSIFs and serious final diagnoses. Systematic radiologist review generated 13 times
more PSIFs than radiographer flagging (179/1000 [17.9%] versus 104/6334 [1.6%]; age-
and sex-adjusted OR 13.3 [95% confidence interval (CI) 10.3–17.1] p<0.001) and propor-
tionally fewer serious final diagnoses (21/179 [11.7%]; 33/104 [31.7%]). Risks of both PSIFs
and of serious final diagnoses increased with age (sex-adjusted ORs [95% CI] for oldest
[67–79 years] versus youngest [44–58 years] participants for PSIFs and serious final diag-
noses respectively: 1.59 [1.07–2.38] and 2.79 [0.86 to 9.0] for systematic radiologist review;
1.88 [1.14–3.09] and 2.99 [1.09–8.19] for radiographer flagging). No other factor was signifi-
cantly associated with either PSIFs or serious final diagnoses. Our study is the largest so far
to investigate the factors associated with PSIFs and serious final diagnoses, but despite
this, we still may have missed some associations due to sparsity of these outcomes within
our cohort and small numbers within some exposure categories.
Conclusion
Risks of PSIFs and serious final diagnosis are substantially influenced by PSIFs protocol
and to a lesser extent by age. As only 1/5 PSIFs represent serious disease, evidence-based
PSIFs protocols are paramount to minimise over-investigation of healthy research partici-
pants and diversion of limited health services away from patients in need.
Introduction
Brain and body imaging is increasingly used for research, diagnostic and screening purposes
and is accompanied by the risk of identifying abnormalities which are unrelated to the pur-
poses of the imaging, so-called incidental findings (IFs) [1]. Since very few IFs turn out to rep-
resent serious disease [2], it is of limited value to feedback clearly non-serious IFs. Therefore,
we focus on potentially serious IFs (PSIFs), defined as those which indicate the possibility of a
condition which, if confirmed, would carry a real prospect of seriously threatening life span, or
of having a substantial impact on major body functions or quality of life [2]. Feedback of PSIFs
detected during research imaging generates some form of clinical assessment (e.g. general
practitioner appointments and specialist referrals, or further investigations including imaging
and invasive procedures) in almost all cases [2]. Information on the factors associated with
increased risk of detection and feedback of a PSIF (and therefore of subsequent clinical assess-
ment), and with increased risk of eventually receiving a serious final diagnosis may influence
individuals’ decisions to consent to participate in imaging research [3–5] and inform research-
ers’ designs of appropriate PSIFs policies, which are required by major research funders [6, 7].
A small number of studies (N = 151 to 5800) which followed-up unselected participants
with PSIFs suggest that PSIFs are associated with age, but not with sex. However none of these
studies investigated the associations of PSIFs with PSIFs protocols, or any factors associated
with serious final diagnoses [8–17].
The UK Biobank Imaging Study provides an opportunity to investigate potential risk fac-
tors for PSIFs and serious final diagnoses. In the UK Biobank Imaging Study, 100,000 of the
original 500,000 participants are undergoing brain, cardiac and body magnetic resonance
imaging (MRI), dual-energy X-ray absorptiometry (DXA) and carotid Doppler ultrasound;
Factors associated with potentially serious incidental findings on imaging and serious final diagnoses
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over 32,000 participants have been imaged as of December 2018] [18]. These imaging data are
linked to detailed sociodemographic, lifestyle, physical measurement, genetic and routine
healthcare data generating an extensive research resource [19].
The UK Biobank Imaging Study will inevitably generate PSIFs. To inform the development
of a pragmatic PSIFs protocol that aims to minimise harm to (the largely asymptomatic)
100,000 imaged participants, UK Biobank reviewed current practice, published literature and
guidance, and sought advice from professional bodies, and from ethical and legal experts [2].
The protocol is based on radiographers flagging images of potential concern to a radiologist
for their review [2, 20]. This approach was evaluated against a protocol involving systematic
radiologist review of all images (which is more commonly used in research studies), and found
to generate less harm (i.e., less unnecessary anxiety to participants and their families) and a
lower burden on the publicly-funded UK National Health Service [2]. UK Biobank is continu-
ing to evaluate this PSIFs protocol through systematic follow-up of all participants identified
with a PSIF.
We aimed to determine whether, and to what extent, socio-demographic, lifestyle, other
health-related factors and PSIFs protocol are associated with detection of both a PSIF and a
final diagnosis of serious disease. We achieved this using data from the first 7,334 participants
imaged during the first 20 months of the UK Biobank Imaging Study (including systematic fol-
low-up of 283 participants with PSIFs).
Methods
We prepared this manuscript according to STROBE guidelines (S1 File) [21]. The statistical
analysis code is available online [22]. UK Biobank obtained ethics approval for the imaging
study, and evaluation of the PSIFs protocol (North West Research Ethics Committee reference
numbers: 11/NW/0382; 16/NW/0274). We provided all participants with written information
about the imaging study and the UK Biobank imaging IFs protocol [23]. All participants pro-
vided written consent to take part in the imaging study, and for UK Biobank to feed back any
identified potentially serious IFs to them and their general practitioner (GP).
UK Biobank Imaging Study
Of 9.2 million adults aged 40–69 invited to participate in UK Biobank, 0.5 million (5.5%) par-
ticipated, providing initial baseline data between 2006 and 2010 [24]. From April 2014 to
December 2015, participants living within approximately 120 km of the imaging centre in
Stockport were further invited to take part in the UK Biobank Imaging Study [25]. Participants
were excluded if they had metal implants, penetrating metal injury, non-removable metallic
items, or if they would find it difficult to complete the imaging, e.g. due to claustrophobia
(Fig 1) [25].
At the imaging visit, participants underwent brain, heart and body MRI, whole-body, spine
and hip DXA and carotid Doppler ultrasound [26–30]. Participants also repeated the UK Bio-
bank baseline assessment, which involved: a touchscreen questionnaire to collect data on
potentially relevant risk factors for diseases, including sociodemographic, lifestyle and medical
history; an interview; and physical measurements [31].
UK Biobank PSIFs protocol
During imaging, UK Biobank radiographers may notice PSIFs and ‘flag’ concerning images
for radiologist review; radiologist-confirmed PSIFs are then fed back to participants and their
GP [2]. To evaluate this PSIFs protocol, all images from the first 1000 participants were also
systematically reviewed by radiologists for PSIFs [2]. Radiographers did not flag any PSIFs in
Factors associated with potentially serious incidental findings on imaging and serious final diagnoses
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addition to those detected by the radiologists within the first 1000 imaged participants [2].
Therefore, for the purposes of this present study, we classified the first 1000 imaged partici-
pants as undergoing the ‘systematic radiologist review’ PSIFs protocol, and subsequently
imaged participants as undergoing the ‘radiographer flagging’ PSIFs protocol. For both proto-
cols, to aid interpretation of images, radiologists received information on participants’ age,
sex, ethnicity, alcohol intake, smoking status, blood pressure, body mass index (BMI), employ-
ment status, and self-reported medical history. The legal and ethical background to the UK
Biobank ‘radiographer flagging’ protocol has been previously described [2].
Participants with PSIFs are surveyed at six weeks and six months after receiving feedback,
while their GPs are surveyed six months after feedback and asked for copies of relevant clinical
correspondence; these responses include data on final diagnoses [2].
Carotid Doppler ultrasound was deemed extremely unlikely to generate PSIFs under UK
Biobank’s protocol [25], as asymptomatic carotid stenosis is rare and the clinical relevance is
not well established, and extra-carotid abnormalities were not likely to be relevant as UK
Fig 1. Participant flowchart.
https://doi.org/10.1371/journal.pone.0218267.g001
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Biobank sonographers are trained in vascular Doppler US only. As such, carotid Doppler US
data are not included in this study.
Data sources and variables
PSIFs and serious final diagnoses. We extracted data on the number, types and body
region of each participant’s PSIF(s) from radiologists’ reports. A consultant physician and an
experienced clinical radiology specialty trainee independently classified final diagnoses using
all available survey data and clinical correspondence; we contacted participants and GPs by
telephone where these data were insufficient to classify final diagnoses [2]. We classified final
diagnoses as either: serious (if they were likely to threaten life span, or have a substantial
impact on quality of life or major body function); not serious (if this was not the case); or inde-
terminate (if there remained insufficient data to classify a final diagnosis as serious or not) [2].
A PSIF which turned out to be a known diagnosis was deemed to be very unlikely have any
additional impact on the participant, and therefore we classified such findings as ‘non-serious.’
classified participants with more than one PSIF according to their most serious final diagnosis
[2].
Participant factors. We selected variables available from UK Biobank [32] which might
be associated with PSIFs or would be possible confounders. These were age, sex, ethnicity,
Townsend socio-economic deprivation score (which may reduce access to healthcare, increase
the risk of disease and reduce opportunities for disease detection prior to research imaging),
use of private healthcare (which may be associated with reduced risk of PSIFs if it increases
prior knowledge of disease), alcohol intake [33], fruit and vegetable intake [34], physical activ-
ity [35], smoking status, body mass index (BMI) [36] and morbidity. We measured the latter
using the Elixhauser Index calculated using Hospital Episode statistics data from two years
before the date of imaging, and defined morbidity as� 1 Elixhauser Index health conditions
[37–39].
Statistical analyses
Since our previous study showed that the ‘systematic radiologist review’ protocol produced
approximately ten times more PSIFs compared with the ‘radiographer flagging’ protocol [2],
all analyses were stratified by PSIFs protocol to control for potential confounding. We com-
pared characteristics between participants with and without PSIFs, and with and without seri-
ous final diagnoses, and calculated age- and sex-adjusted odds ratios (ORs) with 95%
confidence intervals (CIs) using binomial logistic regression models.
We tested for normal distributions of continuous variables by visual inspection of graphed
data and Kolmogorov-Smirnov goodness-of-fit tests. We attempted to normalise non-nor-
mally distributed data using log transformations, and if this failed, recoded variables into cate-
gories, aiming for similar numbers of participants in each category to optimise statistical
efficiency. We used non-parametric tests to compare distributions of non-normally distributed
variables between two groups. We considered data to be missing if participants did not
respond, or if they responded ‘do not know’ or ‘prefer not to answer’; such participants were
excluded only from the relevant analyses. We present summary statistics of the characteristics
of the whole UK Biobank cohort only to inform on the likely influence of factors associated
with PSIFs or serious final diagnoses which may occur as the UK Biobank imaging study con-
tinues; these cannot be compared directly to the imaged sub-cohort included in this study due
to lack of independence of these two samples. The majority of variables had no, or only small
proportions (< 3%) of missing data. In total, 460/7334 (6.3%) participants had missing data
for at least one variable. We performed all analyses using SPSS version 22.
Factors associated with potentially serious incidental findings on imaging and serious final diagnoses
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Results
Participants
By 23rd December 2015, 7,334 of 33,367 invited participants (22.0%) had been imaged and
were included in this study (Fig 1). Median age of the imaged participants was 63 (interquartile
range 56–68) years and 3,804 (51.9%) were women (Table 1).
Compared to the entire UK Biobank cohort, this imaged sub-cohort included lower pro-
portions of women, people of minority ethnicity groups, and people with less healthy lifestyles,
including those with harmful alcohol intake, current smokers, low physical activity levels, or
those who were overweight or obese. Conversely, a higher proportion of the imaged sub-
cohort had one or more health conditions as measured using the Elixhauser Index compared
to the whole cohort (Table 1).
PSIFs and final diagnoses
PSIFs were detected in 283/7,334 (3.9%) people: 179 of the first 1000 (17.9%) by systematic
radiologist review; 104 of the subsequent 6,334 (1.6%) by radiographer flagging (OR for sys-
tematic radiologist review versus radiographer flagging: 13.3, 95% CI 10.3–17.1, p<0.001,
Table 2). The majority of PSIFs were finally diagnosed as clinically non-serious (229/283,
80.9%). Serious final diagnoses occurred in 54/7,334 (0.7%) participants: 21 of the first 1000
(2.1%) undergoing the systematic radiologist review protocol and 33 of the 6,334 (0.5%)
undergoing the radiographer flagging protocol (OR 4.2, 95% CI 2.4–7.4, p<0.001, Table 2).
Radiographer flagging thus resulted in a higher proportion of PSIFs with serious final diagno-
ses than radiologist review (33/104 [31.7%] versus 21/179 [11.7%] respectively). The most
common serious final diagnoses were tumours and vascular diseases (Tables 3, 4 and 5). The
two doctors agreed on the initial classification of final diagnoses in 270/283 (95.4%) of cases,
and readily resolved the 13 cases of disagreement through discussion.
Systematic radiologist review generated higher proportions of PSIFs on all imaged body
regions (OR range 4.3–21.3, all p<0.001, Table 2) compared to radiographer flagging. Radiolo-
gists more commonly detected PSIFs on cardiac (8.1%) and body MRI (8.3%) compared to
brain MRI (2.3%) or DXA (1.4%). In contrast, radiographer flagging generated similar propor-
tions of PSIFs across body regions (range 0.3–0.6%, Table 2). Serious final diagnoses occurred
most commonly on cardiac MRI assessed by systematic radiologist review (13/1000, 1.3%,
Table 2).
Factors associated with PSIFs and serious final diagnoses
Across the relatively narrow age range of the included participants, older age was associated
with an increased odds of PSIFs and of serious final diagnoses under both protocols, albeit not
statistically significant for serious final diagnoses under systematic radiologist review (sex-
adjusted ORs [95% CI] for oldest [67–79 years] versus youngest [44–58 years] participants for
PSIFs and serious final diagnoses respectively: 1.59 [1.07–2.38] and 2.79 [0.86 to 9.0] for sys-
tematic radiologist review; 1.88 [1.14–3.09] and 2.99, 95% CI [1.09–8.19] for radiographer flag-
ging) (Figs 2 and 3). Of the participants with PSIFs, those with serious final diagnoses were
older than those with non-serious final diagnoses (median ages [range minimum-maximum]
in years: 66 [50–76] versus 64 [44–76] respectively, p = 0.021).
Of participants assessed by radiographer flagging, overweight participants had reduced
odds of serious final diagnoses compared to those of normal or underweight BMI (age- and
sex-adjusted OR 0.21, 95% CI 0.08–0.58, p = 0.003, Fig 3), but the number of overweight par-
ticipants was very small (n = 5).
Factors associated with potentially serious incidental findings on imaging and serious final diagnoses
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Table 1. Characteristics of the UK Biobank cohort and the imaged sub-cohort included in this study.
Entire UK Biobank cohort (of whom 100,000 will be imaged)
(N = 502,205)1
n (%)
Imaged UK Biobank sub-cohort included in this study
(N = 7,334)2
n (%)
Sociodemographics
Age3
Median (IQR) 63 (55–68) 63 (56–68)
Sex4
Female 273,224 (54.4) 3804 (51.9)
Male 228,981 (45.6) 3530 (48.1)
Ethnicity5
White 472,493 (94.1) 7023 (95.8)
Minority ethnicity groups 27,012 (5.4) 225 (3.1)
TDI5
Median (IQR) -2.1 (-3.6–0.6) -2.5 (-3.9 –-0.5)
Private healthcare5
Never used 120,934 (70.1) 5377 (73.3)
Ever used 49,980 (29.0) 1850 (25.2)
Lifestyle
Alcohol5,6
None 19,942 (14.1) 848 (11.6)
Moderate 73,886 (52.3) 4124 (56.2)
Hazardous 34,980 (24.8) 1854 (25.3)
Harmful 9,084 (6.4) 376 (5.1)
Smoking5
Never 273,400 (54.4) 4350 (59.3)
Previous 172,980 (34.4) 2575 (35.1)
Current 52,947 (10.5) 319 (4.3)
Fruit and vegetable portions/day5,7
< 5 342,833 (68.3) 5028 (68.6)
� 5 144,064 (28.7) 2141 (29.2)
Days/week of moderate physical activity5,8
0–2 169,162 (33.7) 2149 (29.3)
3–4 118,615 (23.6) 1967 (26.8)
5–7 187,251 (37.3) 2983 (40.7)
Other factors
Morbidity9
None 457,301 (91.1) 6422 (87.6)
�1 condition 44,904 (8.9) 912 (12.4)
BMI5,10
Underweight 2625 (0.5) 47 (0.6)
Normal 162,348 (32.3) 2733 (37.3)
Overweight 212,064 (42.2) 3061 (41.7)
(Continued)
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Table 1. (Continued)
Entire UK Biobank cohort (of whom 100,000 will be imaged)
(N = 502,205)1
n (%)
Imaged UK Biobank sub-cohort included in this study
(N = 7,334)2
n (%)
Obese 122,228 (24.3) 1454 (19.8)
IQR = interquartile range, TDI = Townsend Deprivation Index (higher score indicates greater deprivation), BMI = body mass index
1. Data collected at recruitment visit, unless otherwise indicated.
2. Data collected at the imaging visit, unless otherwise indicated.
3. Age on 30th April 2014, i.e. the start of the imaging study, for the entire cohort, and the imaged cohort.
4. Sex data were only available from the recruitment visit.
5. Data were missing for ethnicity (2,700/502,205 [0.5%], 86/7,334 [1.2%]), TDI (627/502,205 [0.1%], 0/7,334 [0.0%]), private healthcare use (1,694/172,608 [1.0%,
questions on private healthcare were introduced partway through the recruitment period on 29th April 2009, thus giving a smaller denominator], 107/7,334 [1.5%]),
alcohol (3,357/141,149 [2.3%, questions on subtypes of alcoholic drinks were introduced partway through the recruitment period on 29th August 2009, thus giving a
smaller denominator], 132/7,334 [1.8%]), smoking (2,878/502,205 [0.6%], 90/7,334 [1.2%]), fruit and vegetable intake (15,308/502,205 [3.0%], 165/7,334 [2.2%]),
physical activity (27,177/502,205 [5.4%], 235/7,334 [3.2%]), BMI (2,940/502,205 [0.6%], 39/7,334 [0.5%]), from the whole UK Biobank cohort versus the imaged sub-
cohort respectively.
6. We calculated alcohol intake in units per week and categorised these using British Medical Association guidelines (women: moderate > 0 < 14, hazardous 14–35,
harmful > 35; men: moderate >0 < 21, hazardous 21–50, harmful > 50) [33].
7. We calculated portions of fruit and vegetable intake per day, and categorised these into five or more portions per day, or not. [34]
8. Participants were asked ‘in a typical week, on how many days did you do 10 minutes or more of moderate physical activities like carrying light loads, cycling at normal
pace (do not include walking)?’ [35].
9. We calculate morbidity using an Elixhauser Index score [37, 38] based on two-years of routinely collected Hospital Episode Statistics data, looking back from date of
recruitment for the entire UK Biobank cohort, and the date of imaging for the imaged sub-cohort. Routinely collected health data are used to calculate payments for
providers for services delivered for different conditions. The system for applying prices to healthcare services changed in 2012 [39], therefore the numbers of conditions
coded in health records may not be directly comparable between the entire cohort, and the imaged cohort.
10. We defined BMI categories as underweight, normal, overweight and obese as BMIs of <18.5,�18.5 < 25.0,� 25.0 < 30.0,� 30.0 respectively [36].
https://doi.org/10.1371/journal.pone.0218267.t001
Table 2. Odds ratios for potentially serious incidental findings (PSIFs) and serious final diagnoses comparing two protocols.
Systematic radiologist review
(N = 1000)
n (%)1
Radiographer flagging
(N = 6334)
n (%)1
OR (95% CI)2
systematic radiologist review versus radiographer flagging
p-value3
PSIFs 179 (17.9) 104 (1.6) 13.3 (10.3–17.1) <0.001
Brain MRI 23 (2.3) 35 (0.6) 4.3 (2.5–7.3) <0.001
Cardiac MRI 81 (8.1) 29 (0.5) 19.7 (12.8–30.2) <0.001
Body MRI 83 (8.3) 27 (0.4) 21.3 (13.7–33.0) <0.001
DXA 14 (1.4) 16 (0.3) 5.8 (2.8–11.9) <0.001
Serious final diagnoses 21 (2.1) 33 (0.5) 4.2 (2.4–7.4) <0.001
Brain MRI 4 (0.4) 13 (0.2) 2.0 (0.7–6.2) 0.221
Cardiac MRI 13 (1.3) 10 (0.2) 8.5 (3.7–19.5) <0.001
Body MRI 3 (0.3) 5 (0.1) 4.1 (1.0–17.1) 0.056
DXA 1 (0.1) 5 (0.1) 1.3 (0.2–11.0) 0.818
OR = odds ratio, CI = confidence interval, PSIFs = potentially serious incidental findings, MRI = magnetic resonance imaging, DXA = dual energy X-ray
absorptiometry
1. Numerators are the number of participants with at least one PSIF per region. Multiple PSIFs occurred in four participants (who had two PSIFs each) under
radiographer flagging, and in 33 (28 had two and five participants had three PSIFs each) under systematic radiologist review, giving a total of 325 PSIFs; therefore the
sums of the body region PSIFs are greater than the 104 and 179 participants with at least one PSIF respectively. No participant had more than one serious final
diagnosis.
2. Age- and sex-adjusted ORs for PSIFs and serious final diagnoses.
3. p-value from Wald test.
https://doi.org/10.1371/journal.pone.0218267.t002
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No significant associations were found between PSIFs or serious final diagnoses and any
other investigated factor for participants assessed by either PSIFs protocol (Figs 2 and 3).
Discussion
Systematic radiologist review of images resulted in approximately 13 times more PSIFs, and
four times more serious final diagnoses than the radiographer flagging protocol; these effect
sizes are larger than those of any other risk factor assessed for association with either PSIFs or
serious final diagnoses. Most (80%) PSIFs did not turn out to represent serious disease. The
odds of PSIFs and of serious final diagnoses increased with age, regardless of PSIFs protocol.
There were no clear associations between either PSIFs or serious final diagnoses and sex, eth-
nicity, socio-economic deprivation, use of private healthcare, alcohol intake, diet, physical
activity, smoking status, BMI or morbidity among participants assessed using either PSIFs
protocol.
Our study confirms and updates our previous findings from the first 1000 imaged UK Bio-
bank participants [2]: compared to systematic radiologist review, radiographer flagging
resulted in substantially fewer participants with potentially serious IFs and a higher proportion
of these had serious final diagnoses. We also confirm the findings of the above-mentioned
smaller cohort [2], that around 80% of PSIFs do not turn out to represent serious disease.
Table 3. Serious final diagnoses.
Image modality Serious final diagnoses Systematic radiologist review
(N = 1000)
n participants
Radiographer flagging
(N = 6334)
n participants
Brain MRI Arachnoid cyst with hydrocephalus 1 -
Arteriovenous malformation - 1
Cavernoma - 1
Meningioma requiring surgery 1 3
Normal pressure hydrocephalus - 1
Pituitary tumour 2 4
Pleomorphic adenoma requiring surgery - 1
Vestibular schwannoma - 2
Cardiac MRI Atrial fibrillation 1 1
Cardiomyopathy 2 3
Coronary heart disease 1 -
Heart block and LV impairment 1 -
Lung tumour 3 -
Mesothelioma - 1
Myxoma - 1
Severe valve disease - 2
Thoracic aortic aneurysm 5 2
Body MRI: Abdomen Abdominal aortic aneurysm > 5 cm 1 1
Colonic tumour - 1
Gastrointestinal stromal tumour 1 -
Pancreatic tumour 1 1
Renal tumour - 2
DXA Osteoporotic crush fracture 1 5
All modalities: serious final diagnoses 21 33
MRI = magnetic resonance imaging, LV = left ventricular, DXA = dual-energy X-ray absorptiometry,— = zero
https://doi.org/10.1371/journal.pone.0218267.t003
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Previous studies, mostly of brain MRI, found that PSIFs were associated with increased
age [10, 13, 15, 17], but not clearly associated with sex [8–16]. We have further confirmed
these findings in participants undergoing multimodal imaging of multiple body regions, and
shown this to be independent of the IFs protocol. Previous studies did not demonstrate any
Table 4. Non-serious final diagnoses.
Image modality Non-serious final diagnoses Systematic radiologist review
(N = 1000)
n participants
Radiographer flagging
(N = 6334)
n participants
Brain MRI Already known diagnosis 1 3
Benign cyst/lesion 15 10
Hydrocephalus (not serious) - 2
Suspected lesion not confirmed 3 3
Cardiac MRI Already known cardiac diagnosis 7 5
Already known lung diagnosis 2 1
Already under investigation - 1
Cardiac diagnosis—not serious 8 8
Lung diagnosis—not serious 28 2
Other non-serious diagnosis 10 1
Suspected lesion not confirmed 18 1
Body MRI: Abdomen Abdominal aortic aneurysm < 5cm 2 1
Already known diagnosis 4 3
Benign lesion (e.g. cyst) 57 14
Other non-serious diagnosis 4 -
Suspected lesion not confirmed 13 2
Body MRI: Leg Already known diagnosis 1 -
Bone/soft tissue diagnosis—not serious 5 -
Suspected lesion not confirmed 2 -
DXA Already known diagnosis 5 5
Non-serious diagnosis 5 3
Suspected lesion not confirmed 2 2
All modalities: non-serious final diagnoses 192 67
MRI = magnetic resonance imaging, DXA = dual-energy X-ray absorptiometry,— = zero
https://doi.org/10.1371/journal.pone.0218267.t004
Table 5. Uncertain final diagnoses.
Image modality Uncertain final diagnoses Systematic radiologist review
(N = 1000)
n participants
Radiographer flagging
(N = 6334)
n participants
Brain MRI Lesion, unclear nature - 4
Cardiac MRI Lung consolidation, unclear nature 1 1
Lung nodule, unclear nature 2 -
Body MRI: Abdomen Cysts, unclear nature - 2
DXA Crush fracture T11, unclear relevance 1 -
Fractures, unclear cause - 1
All modalities: uncertain final diagnoses 4 8
MRI = magnetic resonance imaging, DXA = dual-energy X-ray absorptiometry,— = zero
https://doi.org/10.1371/journal.pone.0218267.t005
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associations with PSIFs and medical history of cardiac disease [10], psychotic episodes [40] or
human-immunodeficiency virus [41]. Given the varying nature of PSIFs (tumours, aneurysms
etc.), a common biological risk factor seems unlikely. Instead, we captured morbidity using
the Elixhauser Index, which comprises 30 conditions [37, 38]. There was no convincing associ-
ation between morbidity and either PSIFs or serious final diagnoses, but sparse data on both of
these outcomes and exposure data on morbidity (which may be secondary to healthy volunteer
bias and a relatively short period of retrospective capture within linked hospital admissions
data, chosen to limit any bias that may arise from changes in healthcare record coding prac-
tices in 2012 [39]) may have attenuated any true association. Furthermore, different definitions
of morbidity may well produce different results.
Large studies are needed to investigate the factors associated with PSIFs and with serious
final diagnoses, as these outcomes are relatively rare, particularly under a protocol of radiogra-
pher flagging. Our study is the largest so far to investigate the factors associated with PSIFs,
and the first to investigate factors associated with serious final diagnoses, in unselected, healthy
Fig 2. Age- and sex-adjusted odds ratios for potentially serious incidental findings (PSIFs) stratified by PSIFs protocol. PSIFs = potentially serious incidental
findings, OR = odds ratio, CI = confidence interval, TDI = Townsend Deprivation Index, BMI = body mass index. Circles are weighted by the proportion of
participants within a category. 1. Age- and sex-adjusted ORs, except age tertiles which are adjusted for sex only, and sex which is adjusted for age only. 2. p-value
from Wald test. 3. Data were missing for ethnicity (13/1000 [1.3%], 73/6334 [1.2%]), TDI (1/1000 [0.1%], 3/6334 [<0.0%]), private healthcare use (15/1000 [1.5%],
92/6334 [1.5%]), alcohol (20/1000 [2.0%], 112/6334 [1.8%]), smoking (12/1000 [1.2%], 78/6334 [1.2%]), fruit and vegetable intake (27/1000 [2.7%], 138/6334
[2.2%]), physical activity (35/1000 [3.5%], 200/6334 [3.2%]) and BMI (5/1000 [0.5%], 34/6334 [0.5%]), for participants assessed by systematic radiologist review
and by radiographer flagging respectively. 4. We calculated alcohol intake, fruit and vegetable intake, physical activity, morbidity and BMI as described in the
footnotes to Table 1.
https://doi.org/10.1371/journal.pone.0218267.g002
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participants undergoing MRI of any body region. Our sample is approximately 25% larger
than the largest previous study of factors associated with PSIFs detected on brain MRI
(N = 5,800) [8] and 50 times larger than the largest previous such study of multi-region MRI
(N = 148) [16]. We systematically followed-up 50% more participants for data on final diagno-
ses compared to the largest previous study (N = 188) [8]. Despite the size of our study, we still
may have missed associations with PSIFs or final diagnoses due to sparsity of these outcomes
within our cohort and small numbers within some exposure categories (e.g. minority ethnicity
groups). Healthy volunteer selection bias likely affects the UK Biobank cohort, as participants
are less deprived than non-participants and less likely to be obese, smoke, drink alcohol daily
or have self-reported medical conditions compared to the general population [24]. The imaged
cohort are then further selected, with lower proportions of people having more ‘unhealthy’ life-
styles; imaged participants have survived and also remain healthy enough to travel to the imag-
ing centres and undergo the imaging assessment. As with all epidemiological studies which
use self-reported data, our data on exposures may be further limited by reporting bias; partici-
pants may have inaccurately reported alcohol intake, smoking habits, physical activity and
diet. The apparently reduced odds of serious final diagnoses in overweight participants may be
Fig 3. Age- and sex-adjusted odds ratios for serious final diagnoses stratified by PSIFs protocol. OR = odds ratio, CI = confidence interval, TDI = Townsend
Deprivation Index, BMI = body mass index. Circles are weighted by the proportion of participants within a category. 1. Age- and sex-adjusted ORs, except age
tertiles which are adjusted for sex only, and sex which is adjusted for age only. 2. p-value from Wald test. 3. Data were missing as described in Fig 2, footnote 3. 4.
We calculated alcohol intake, fruit and vegetable intake, physical activity, morbidity and BMI as described in the footnotes to Table 1.
https://doi.org/10.1371/journal.pone.0218267.g003
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spurious, secondary to data sparsity of both the outcome and the exposure. The direction of an
association (if any) between increased BMI and PSIFs is unclear. The associations between
increased BMI and certain cancers [42] may lead to increased risk of PSIFs and serious final
diagnoses; alternatively, risks may be reduced if people with increased BMI tend not to com-
plete all MRI sequences, or imaging of all body regions.
Our classifications of ‘serious’ final diagnoses are based on clinical judgement using data
collected up to six months after feedback of a PSIF. Reaching final diagnoses of some PSIFs
may take longer [2]. Feedback of PSIFs may impact on non-medical domains such as emo-
tional wellbeing, insurance and finances and work and activities, regardless of the health-
related severity of the final diagnosis [2]. ‘Severity’ of a final diagnosis is therefore inherently
difficult to judge, though we did show good agreement between two independent physicians’
classifications using a medical-based definition.
By deliberately focusing our study on participants with PSIFs and serious final diagnoses
our results inform on factors associated with findings which are likely to generate clinical
assessment, and those with serious health consequences, respectively. While our cohort is not
representative of the general population, exposure-outcome associations can be generalised to
other populations [24, 43, 44], to inform the design of appropriate IFs handling policies, which
are required by major funders,[7] and of materials to facilitate the informed consent of poten-
tial research participants.
Compared to sociodemographic, lifestyle and health-related factors, the protocol for
identifying PSIFs protocol has by far the largest influence on the generation of PSIFs and
serious final diagnoses. As the majority of PSIFs do not turn out to be serious, but feedback
generates clinical assessments and negative impacts on emotional wellbeing, insurance and
finances and work and activities [2], our study suggests that researchers have the opportu-
nity to greatly influence (for better or worse) the potential harms done to participants and
the burden on publicly-funded health services. There remain many unanswered questions
on the impacts of different methodologies to feedback research results to participants [45];
to inform future policy design, evaluations of the impacts of different protocols are
paramount.
PSIFs are rare, and few are finally diagnosed as serious disease; hence large studies are
needed to investigate the associated factors. This study represents the largest such cohort so
far. Furthermore, since 100,000 participants will complete the UK Biobank imaging assess-
ment over the next few years, it will in due course be possible to update these analyses with a
substantially larger sample size, providing more comprehensive and statistically better pow-
ered estimates of the factors associated with PSIFs and with serious final diagnoses.
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